Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects With Chronic Anemia

NCT03802201 is registered in ClinicalTrials.gov with Protagonist Therapeutics, Inc. as lead sponsor.

NCT NCT03802201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03802201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects With Chronic Anemia
Lead sponsor
Protagonist Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 19, 2018
Completion date
July 31, 2020
Enrollment
63 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

chronic anemia, ineffective erythropoiesis, β-thalassemia